Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Controlled, Open-label, Phase II Trial on Autologous Tumor Infiltrating Lymphocyte Injection (LM103 TILs) for the Treatment of Advanced Melanoma

NCT07310784 is registered in ClinicalTrials.gov with Suzhou BlueHorse Therapeutics Co., Ltd. as lead sponsor.

NCT NCT07310784
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07310784 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Controlled, Open-label, Phase II Trial on Autologous Tumor Infiltrating Lymphocyte Injection (LM103 TILs) for the Treatment of Advanced Melanoma
Lead sponsor
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
December 16, 2025
Completion date
December 31, 2028
Enrollment
92 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

advanced melanoma